Abstract
A number of pharmaceuticals, including antidepressants and antiepileptics, have a strong correlation with suicide risk. However few studies based on real-world data have been published. This study aims to investigates the correlation between certain pharmaceuticals and the risk of suicidal ideation or self-injurious behavior. Utilizing the FDA Adverse Event Reporting System (FAERS) database, we conducted an analysis to identify drugs linked to these adverse outcomes, employing the High-Level Term (HLT) classification from the MedDRA dictionary. By assessing the reporting intensity of the HLT "suicidal ideation or self-injurious behavior" and its Preferred Terms (PTs) across various drug categories with the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR), we pinpointed the top 20 medications with the highest association. These included sedative-hypnotics, antidepressants, antipsychotics, antiepileptic drugs, antihypertensives, antipyretics/analgesics, and antihyperglycemics. Ranking by ROR, the drugs with the strongest association were alprazolam, zolpidem, bupropion, quetiapine, and fluoxetine. Different categories of drugs are on the table for various reasons. This study provides a nuanced and scientifically rigorous examination of the link between diverse drug categories and the reporting frequency of suicide and self-injury, presenting valuable information for improved medication management and patient safety.